| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said he prefers Netflix, Inc. (NASDAQ:NFLX) over fuboTV Inc. (NYSE:FUBO).
FuboTV reported earnings for the third quarter of 2025 on Nov. 3. Revenue of the sports-first live TV streaming platform declined 2.3% year-over-year (Y/Y) to $377.20 million, topping the analyst consensus estimate of $361.33 million.
When asked about Rocket Companies, Inc. (NYSE:RKT), he said, “No one's buying homes here.”
On the earnings front, Rocket Companies, on Oct. 30, reported quarterly earnings of 7 cents per share, which beat the Street estimate of 5 cents. Quarterly revenue clocked in at $1.78 billion, which beat the consensus estimate of $1.66 billion.
Cramer said he should have been recommending Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). “It's coming right back right now,” he noted.
As per recent news, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO), with up to every 8-week dosing after an initial monthly dosing period.
Price Action:
Read Next:
Image created using photos from Shutterstock.
